Clinical Trial Update: 28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety and activity of 5 escalating doses of SAR366234 plus a single dose of latanoprost in open-angle glaucoma or ocular hypertension;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• Latanoprost (Latanoprost)
• SAR366234

Snippet

Sponsor: Sanofi | Conditions: Open Angle Glaucoma -Ocular Hypertension | Phase 1 | Status: COMPLETED